<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563433</url>
  </required_header>
  <id_info>
    <org_study_id>MSI-78-304</org_study_id>
    <nct_id>NCT00563433</nct_id>
  </id_info>
  <brief_title>MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers</brief_title>
  <official_title>MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abeona Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genaera Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abeona Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78)&#xD;
      or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone&#xD;
      antibiotic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 224 adults will be enrolled in an outpatient Phase III study to compare the&#xD;
      safety and efficacy of topically applied magainin peptide (MSI-78) to that of ofloxacin&#xD;
      (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic, in the&#xD;
      treatment of infected diabetic foot ulcers.&#xD;
&#xD;
      This is a randomized, controlled, double-blind trial that will involve twenty or more&#xD;
      clinical centers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1994</start_date>
  <completion_date type="Actual">July 1996</completion_date>
  <primary_completion_date type="Actual">July 1996</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in clinical signs and symptoms of infection</measure>
    <time_frame>Study day 10</time_frame>
    <description>Measure will be a comparison of the reduction in clinical signs and symptoms of infection between MSI-78 topical therapy and conventional oral antibiotic therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological response</measure>
    <time_frame>Study day 10</time_frame>
    <description>Measure microbiological response to therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound infection score</measure>
    <time_frame>Study day 10</time_frame>
    <description>Measure wound infection score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total wound score</measure>
    <time_frame>Study day 10</time_frame>
    <description>Measure total wound score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound area</measure>
    <time_frame>Study day 10</time_frame>
    <description>Measure wound area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound depth.</measure>
    <time_frame>Study day 10</time_frame>
    <description>Measure wound depth.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">342</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>ofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSI-78</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ofloxacin</intervention_name>
    <description>400 mg twice a day for 14 days</description>
    <arm_group_label>ofloxacin</arm_group_label>
    <other_name>Floxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSI-78</intervention_name>
    <description>1%/2% topical cream twice a day for 14 days</description>
    <arm_group_label>MSI-78</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-hospitalized ambulatory patients with diabetes mellitus&#xD;
&#xD;
          -  Men or Women greater than 18 years old&#xD;
&#xD;
          -  Patients must be considered reliable, willing and able to give consent&#xD;
&#xD;
          -  Female patients must be postmenopausal for a least 6 months or surgically sterilized&#xD;
&#xD;
          -  Localized infection of the ulcer that would ordinarily be treated on an outpatient&#xD;
             basis&#xD;
&#xD;
          -  Patients who have been previously treated or are currently under treatment for a&#xD;
             localized infections of an ulcer may be enrolled in there has been an adequate&#xD;
             response to treatment and ulcer is still infected&#xD;
&#xD;
          -  Patient must have radiograph within two weeks of entry showing no evidence of cortical&#xD;
             destruction consistent with osteomyelitis&#xD;
&#xD;
          -  Patient must have a palpable dorsalis pedis or posterior tibial pulse in the affected&#xD;
             foot&#xD;
&#xD;
          -  Patient may not be taking or have received any other investigational therapy or&#xD;
             approved therapy within 30 days prior to entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients requiring concurrent local or systemic antimicrobials during the study period&#xD;
             for other infections&#xD;
&#xD;
          -  Patients who are currently treated or awaiting dialysis&#xD;
&#xD;
          -  Patients who are unable to care for their ulcers&#xD;
&#xD;
          -  Patients with known alcohol or substance abuse within 6 months or study entry&#xD;
&#xD;
          -  Patients with significant GI problems or surgery that might interfere with the&#xD;
             absorption of ofloxacin&#xD;
&#xD;
          -  Patients who are currently receiving systemic corticosteroids, immunosuppressives,&#xD;
             antivirals, radiation therapy or cytotoxic agents&#xD;
&#xD;
          -  Patients who currently require treatment or a primary or metastatic malignancy or have&#xD;
             systemically immunocompromising disease.&#xD;
&#xD;
          -  Previous enrollment in this study or previous treatment with MSI-78 Topical Cream&#xD;
&#xD;
          -  Patients with gangrene or severely impaired arterial supply to any portion of the&#xD;
             affected foot&#xD;
&#xD;
          -  Other conditions considered by the investigator to be sound reason for&#xD;
             disqualification&#xD;
&#xD;
          -  Patients with any known allergy to ofloxacin, other quinolone antibiotics, magainin&#xD;
             peptides or ingredients of the vehicle cream&#xD;
&#xD;
          -  Women who are breast feeding, pregnant or attempting to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Litka, MD</last_name>
    <role>Study Director</role>
    <affiliation>Magainin Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle VA Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108-1597</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>foot</keyword>
  <keyword>ulcers</keyword>
  <keyword>Floxin</keyword>
  <keyword>oral antibiotic</keyword>
  <keyword>topical cream</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

